Home / Investments / Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

The biotech drugmaker has a market value of roughly $10 billion, meaning that Gilead would be paying up for the company and its prized breast-cancer drug.

About Helen Hague

Avatar

Check Also

Steve Cohen's Point72 Settles With Female Employee in Gender Discrimination Arbitration

Steven A. Cohen’s Point72 Asset Management recently reached a settlement with a female employee who …

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

css.php
Font Resize